Xifaxan Monotherapy Shows Superiority to Lactulose in Reducing Hepatic Encephalopathy Recurrence
Key Insights
Analysis of two randomized trials reveals that Xifaxan monotherapy is more effective than lactulose in reducing overt hepatic encephalopathy (search) (OHE) recurrence and mortality.
New data highlights Xifaxan's impact on reducing rehospitalizations for OHE in both commercially insured and Medicare patient populations.
Plenvu's efficacy as a bowel preparation medication is confirmed in colonoscopy patients with comorbid conditions or those on medications affecting bowel prep quality.
Bausch Health's Salix Pharmaceuticals is presenting new data at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting, showcasing key analyses of Xifaxan (rifaximin) and Plenvu. A highlight is the Presidential Plenary presentation comparing Xifaxan monotherapy to lactulose monotherapy in reducing overt hepatic encephalopathy (search) (OHE) recurrence and mortality.
Xifaxan Monotherapy vs. Lactulose in OHE Recurrence
A post hoc analysis of two randomized trials evaluated the efficacy of Xifaxan monotherapy compared to lactulose monotherapy for reducing the risk of overt hepatic encephalopathy (search) (OHE) recurrence and all-cause mortality. The data suggests that Xifaxan is more effective in this regard.
Jasmohan S. Bajaj et.al. presented the analysis, titled "Rifaximin Monotherapy Is More Effective Than Lactulose Monotherapy for Reducing the Risk of Overt Hepatic Encephalopathy (search) (OHE) Recurrence and All-Cause Mortality: An Analysis of Two Randomized Trials" during the Presidential Plenary Session.
Impact on OHE Rehospitalizations
Salix is also presenting new data on the impact of Xifaxan use on rehospitalizations following an OHE hospitalization discharge in both commercially insured and Medicare patient populations. This analysis provides insights into the real-world effectiveness of Xifaxan in preventing OHE-related hospital readmissions.
Arun B. Jesudian et.al. presented the "Impact of Rifaximin Use on Overt Hepatic Encephalopathy (search) (OHE) Rehospitalizations Post Discharge from an OHE Hospitalization in Commercially and Medicare Insured Patients".
Plenvu Efficacy in Bowel Preparation
Two posters at the ACG meeting share findings for Plenvu (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride, and potassium chloride for oral solution) as a bowel preparation medication. The studies include efficacy findings from colonoscopy patients with comorbid conditions or those taking concomitant medications known to impact bowel prep quality.
Brooks D. Cash et.al. presented "Efficacy and Safety of the 1 Liter NER1006 Bowel Preparation for Colonoscopy in Adults With Comorbid Conditions That May Impact Prep Quality", while David Poppers et.al. shared that "One-Liter NER1006 Is Efficacious as a Bowel Preparation for Colonoscopy in Patients Taking Concomitant Medications Known to Impact Prep Quality".
Salix Pharmaceuticals' Commitment
"These presentations at ACG 2024 can give healthcare professionals confidence that treatments from Salix have potential to improve outcomes for their patients," said Aimee Lenar, Executive Vice President, US Pharma at Bausch Health. "Bausch Health remains dedicated to pursuing life-changing solutions and continues to invest in expanding the body of evidence for our medicines today and in the future."